Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Tsveta Milanova sold 2,804 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Agios Pharmaceuticals Stock Performance

AGIO traded up $1.58 on Tuesday, hitting $35.12. 1,196,971 shares of the company were exchanged, compared to its average volume of 1,247,393. Agios Pharmaceuticals, Inc. has a fifty-two week low of $20.96 and a fifty-two week high of $62.58. The firm has a market capitalization of $2.00 billion, a P/E ratio of 3.09 and a beta of 0.87. The business's fifty day moving average is $47.38 and its 200 day moving average is $45.70.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on AGIO shares. Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 27th. Royal Bank of Canada boosted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. Raymond James restated an "outperform" rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Leerink Partners lowered shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Finally, StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 9th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $56.33.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Nordea Investment Management AB boosted its position in Agios Pharmaceuticals by 3.6% during the fourth quarter. Nordea Investment Management AB now owns 220,569 shares of the biopharmaceutical company's stock worth $7,191,000 after acquiring an additional 7,593 shares during the last quarter. Exome Asset Management LLC acquired a new position in Agios Pharmaceuticals in the third quarter valued at $2,941,000. Franklin Resources Inc. acquired a new stake in Agios Pharmaceuticals in the 3rd quarter worth about $1,499,000. Geode Capital Management LLC grew its holdings in Agios Pharmaceuticals by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company's stock valued at $60,326,000 after buying an additional 6,101 shares during the period. Finally, Frazier Life Sciences Management L.P. increased its stake in shares of Agios Pharmaceuticals by 19.7% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company's stock valued at $46,392,000 after acquiring an additional 172,180 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.